As part of the research collaboration, Riboxx will provide access to Riboxxim to enable CNBG to perform an evaluation, in conjunction with CNBG’s antigen, against the disease target.
Riboxx CEO Dr. Jacques Rohayem said the firm is delighted to collaborate with CNBG, which is one of the leading developers of vaccines against serious infectious diseases.
"Our TLR3 agonist has the potential to increase the efficacy of the antigen and provide a safe but highly effective immune response against the disease," Rohayem added.